कंपनी का अवलोकन
Daxor Corporation (DXR) operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry by developing specialized medical instrumentation and biotechnology solutions. The company's core operations revolve around the creation of the BVA-100 Blood Volume Analyzer, a distinct instrument designed to measure human blood volume when utilized in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. This entity functions as a micro-cap enterprise with a total market capitalization of $54.78 million, generating annual revenue of $26,688 over the trailing twelve-month period. With an employee count listed as N/A, the organization represents a highly specialized niche player rather than a large-scale industrial manufacturer. The extremely low revenue figure relative to the market cap indicates a significant disparity between the company's earnings power and its current valuation, suggesting that the market price is detached from traditional revenue-based sizing metrics for small-cap medical device firms.
वित्तीय स्वास्थ्य
The financial statements for Daxor Corporation show a revenue of $26,688 and a net income of $9.17 million, while the EBITDA metric is not available for this reporting period. The substantial gap between the negligible revenue of $26,688 and the positive net income of $9.17 million reveals an anomalous cost structure where reported costs are either significantly understated or the revenue classification does not align with the income statement recognition, resulting in a profit margin that defies standard operational logic. The company reports free cash flow of $100,248, which suggests a theoretical capacity for financial flexibility despite the irregularity in the revenue-to-income relationship. However, the gross margin stands at 100.0%, indicating that all revenue is being recorded as gross profit, whereas the operating margin is reported at -9660.6% and the profit margin at 34359.2%, highlighting severe accounting discrepancies or non-operating factors dominating the income statement. On the balance sheet, the company holds N/A in cash and carries $0 in debt, creating a situation where total assets are leveraged against equity despite the negative return on assets. The debt-to-equity ratio is listed as N/A, further obscuring the traditional leverage picture, while the current ratio is 0.08, indicating that short-term liabilities significantly exceed short-term assets and pointing to potential liquidity constraints. Return on Equity is calculated at 22.5%, suggesting high efficiency in generating equity returns, whereas Return on Assets is -1.6%, revealing that the asset base is currently failing to generate positive returns relative to the total asset valuation.
मूल्यांकन आकलन
The trailing P/E ratio is 5.73, while the forward P/E is N/A, implying that analysts do not have a consensus on future earnings growth or that the lack of reliable forward earnings prevents a standard projection of the earnings trajectory. The price-to-book ratio is 1.04, which indicates that the market values the company at approximately 1.04 times its book value, suggesting a valuation that is nearly aligned with the net asset value despite the distorted income figures. The price-to-sales ratio is 2052.45, an exceptionally high multiple that suggests the market is pricing in future growth expectations or is reacting to the unique biotechnology nature of the BVA-100 Blood Volume Analyzer rather than current sales performance. The EV/EBITDA metric is N/A, rendering traditional enterprise value multiples inapplicable for direct comparison with peers that have positive EBITDA figures. The stock has traded between a 52-week high of $14.76 and a 52-week low of $7.10, placing the current valuation within a volatile range that reflects high investor sentiment swings typical of micro-cap biotech instruments. The beta value is 0.14, indicating that the stock price exhibits very low volatility relative to the broader market, moving less than one-seventh as much as the overall market index.
Growth & Income
The revenue growth year-over-year is -82.6%, while the earnings growth year-over-year is 329.3%, demonstrating a divergence where earnings are growing significantly faster than revenue due to the aforementioned accounting anomalies. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all its earnings rather than distributing them to shareholders. This reinvestment strategy, combined with the massive earnings growth rate, implies that management is theoretically channeling capital back into the business, although the negative revenue growth complicates the sustainability of this earnings expansion. The overall growth and income profile is characterized by extreme inconsistency between declining sales figures and exploding net income, alongside a lack of dividend distribution. The company's financial narrative is driven by high efficiency metrics like ROE and free cash flow, yet obscured by the lack of standard liquidity ratios and the absence of a dividend yield, creating a unique investment profile that relies heavily on the interpretation of its non-standard financial data points.